Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin

Vaccine

Volumn 26, Issue 4, 2008, Pages 469-476

  Tsuji, Takao ^a   Shimizu, Takeshi ^b   Sasaki, Keiko ^a   Shimizu, Yoshiyasu ^a   Tsukamoto, Kentaro ^a   Arimitsu, Hideyuki ^a   Ochi, Sadayuki ^a   Sugiyama, Satoshi ^a   Taniguchi, Koki ^a   Neri, Paola ^c   Mori, Hiroshi ^c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Heat labile enterotoxin; Mucosal adjuvant; Stx2b

Indexed keywords

CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; NEUTRALIZING ANTIBODY; POLYHISTIDINE TAG; SHIGA TOXIN 2B; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL FILTRATION CHROMATOGRAPHY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXEMIA; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL VACCINES; CHOLERA TOXIN; CHROMATOGRAPHY, GEL; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HISTIDINE; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; LUNG; MICE; MICE, INBRED ICR; MUCOUS MEMBRANE; MUTATION; NEUTRALIZATION TESTS; POLYMERS; PROTEIN SUBUNITS; SHIGA TOXIN 2; TOXEMIA; VACCINES, SUBUNIT;

EID: 37849003390     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.038     Document Type: Article

References (35)

1. Cleary T.G. The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome. Semin Pediatr Infect Dis 15 (2004) 260-265
2. Karmali M.A. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 26 (2004) 117-122
3. Tarr P.I., Gordon C.A., and Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365 (2005) 1073-1086
4. Su C., and Brandt L.J. Escherichia coli O157:H7 infection in humans. Ann Int Med 123 (1995) 698-714
5. Watanabe M., Igai K., Matsuoka K., Miyagawa A., Watanabe T., Yanoshita R., et al. Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infect Immun 74 (2006) 1984-1988
6. Mukherjee J., Chios K., Fishwild D., Hudson D., O'Donnell S., Rich S.M., et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun 70 (2002) 612-619
7. Yamagami S., Motoki M., Kimura T., Izumi H., Takeda T., Katsuura Y., et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis 184 (2001) 738-742
8. Neill M.A. Treatment of disease due to Shiga toxin-producing Escherichia coli: infectious disease management. In: Kaper J.B., and O'Brien A.D. (Eds). Escherichia coli O157: H7 and other Shiga toxin-producing E. coli strains (1983), ASM Press, Washington DC 357-363
9. Fraser M.E., Chernaia M.M., Kozlov Y.V., and James M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat Struct Biol 1 (1994) 59-64
10. Fraser M.E., Fujinaga M., Cherney M.M., Melton-Celsa A.R., Twiddy E.M., O'Brien A.D., et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279 (2004) 27511-27517
11. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., and Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171 (1988) 45-50
12. Reisbig R., Olsnes S., and Eiklid K. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. J Biol Chem 256 (1981) 8739-8744
13. Hashimoto H., Mizukoshi K., Nishi M., Kawakita T., Hasui S., Kato Y., et al. Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan. Pediatrics 103 (1999) E2
14. Kleanthous H., Smith H.R., Scotland S.M., Gross R.J., Rowe B., et al. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2. Microbiological aspects. Arch Dis Child 65 (1990) 722-727
15. Ostroff S.M., Tarr P.I., Neill M.A., Lewis J.H., Hargrett-Bean N., and Kobayashi J.M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160 (1989) 994-998
16. Scotland S.M., Willshaw G.A., Smith H.R., and Rowe B. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect 99 (1987) 613-624
17. Marcato P., Griener T.P., Mulvey G.L., and Armstrong G.D. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun 73 (2005) 6523-6529
18. Marcato P., Mulvey G., Read R.J., Vander Helm K., Nation P.N., and Armstrong G.D. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 183 (2001) 435-443
19. Acheson D.W., De Breucker S.A., Jacewicz M., Lincicome L.L., Donohue-Rolfe A., Kane A.V., et al. Expression and purification of Shiga-like toxin II B subunits. Infect Immun 63 (1995) 301-308
20. Byun Y., Ohmura M., Fujihashi K., Yamamoto S., McGhee J.R., Udaka S., et al. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 19 (2001) 2061-2070
21. McGhee J.R., Czerkinsky C., and Mestecky J. Mucosal vaccines. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., and McGhee J.R. (Eds). Mucosal immunity (1999), Academic Press, New York 741-757
22. Holmgren J., Lycke N., and Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11 (1993) 1179-1184
23. Lycke N., Tsuji T., and Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 22 (1992) 2277-2281
24. Tamura S., Asanuma H., Tomita T., Komase K., Kawahara K., Danbara H., et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12 (1994) 1083-1089
25. Dickinson B.L., and Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63 (1995) 1617-1623
26. Tsuji T., Yokochi T., Kamiya H., Kawamoto Y., Miyama A., and Asano Y. Relationship between low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology 90 (1997) 176-182
27. Shimizu T., Kawakami S., Sata T., Sasaki T., Higashide M., Hamabata T., et al. The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli. Infect Immun 75 (2007) 2189-2200
28. Takahashi H., Sasaki K., Takahashi M., Shigemori N., Honda S., Arimitsu H., et al. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4(+) and CD8(+) T cells to nasal killed-bacillus calmette-guerin in mice. Vaccine 24 (2006) 3591-3598
29. Sasaki K., Kato M., Takahashi T., Ochi S., Ichinose Y., Shiraki K., et al. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice. J Med Virol 70 (2003) 329-335
30. Yokoyama S., Suzuki T., Ohishi N., Yagi K., Ichihara S., Itoh S., et al. Construction of deletion mutants of Shiga (-like) toxin genes (stx1 or/and stx2) on enterohemorrhagic Escherichia coli (O157:H7). J Clin Biochem Nutr 30 (2001) 33-44
31. Nakajima H., Katagiri Y.U., Kiyokawa N., Taguchi T., Suzuki T., Sekino T., et al. Single-step method for purification of Shiga toxin-1 B subunit using receptor-mediated affinity chromatography by globotriaosylceramide-conjugated octyl sepharose CL-4B. Protein Expr Purif 22 (2001) 267-275
32. Donohue-Rolf A., Keuch G.T., Edson C., Thorley-Lawson D., and Jacewicz M. Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shiga toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and ployclonal antidotes. J Exp Med 160 (1984) 1767-1781
33. Strockine N.A., Marques L.R., Holmes R.K., and O'Brien A.D. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 50 (1985) 695-700
34. Acheson D.W.K., Levine M.M., Kaper J., and Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 64 (1996) 355-357
35. Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M., et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem 280 (2005) 35164-35171